STATegics, Inc. is focused on the discovery and development
of breakthrough new treatments for life-threatening rare neurodegenerative
diseases. By targeting the tissue-protective cytokine receptor, STATegics has
identified novel small molecules to address the underlying cause of
Friedreich’s ataxia (FA), a rare neuromuscular disease for which no treatment
is available. In addition to addressing
critical drivers in FA, STATegics’ molecules have the potential to treat
multiple neuromuscular and neurodegenerative diseases.
